{"generic":"Azithromycin","drugs":["AzaSite","Azithromycin","Zithromax","Zithromax Tri-Pak","Zithromax Z-Pak","Zmax"],"mono":{"0":{"id":"928480-s-0","title":"Generic Names","mono":"Azithromycin"},"1":{"id":"928480-s-1","title":"Dosing and Indications","sub":[{"id":"928480-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Acute infective exacerbation of chronic obstructive pulmonary disease (Mild to Moderate):<\/b> 500 mg ORALLY once daily for 3 days OR 500 mg ORALLY on day 1 followed by 250 mg\/day ORALLY on days 2 to 5<\/li><li><b>Babesiosis:<\/b> 500 to 1000 mg ORALLY on day 1 followed by 250 mg\/day thereafter plus atovaquone 750 mg ORALLY every 12 hours for 7 to 10 days; 600 to 1000 mg\/day of azithromycin may be used in immunocompromised patients<\/li><li><b>Bacterial conjunctivitis:<\/b> 1 drop of 1% solution instilled into the affected eye(s) twice daily (8 to 12 hours apart) for 2 days, followed by 1 drop once daily for an additional 5 days<\/li><li><b>Bacterial endocarditis; Prophylaxis:<\/b> (high-risk patients; dental, respiratory, or infected skin\/skin structure or musculoskeletal tissue procedures) 500 mg ORALLY 30 to 60 minutes prior to procedure<\/li><li><b>Bacterial sinusitis, acute (Mild to Moderate):<\/b> tablets, 500 mg ORALLY daily for 3 days<\/li><li><b>Bacterial sinusitis, acute (Mild to Moderate):<\/b> extended-release oral suspension, a single 2-g ORAL dose<\/li><li><b>Bartonellosis - HIV infection:<\/b> (bacillary angiomatosis, peliosis hepatis, bacteremia, osteomyelitis) 500 mg ORALLY daily for at least 3 months<\/li><li><b>Chancroid:<\/b> 1 g ORALLY as a single dose<\/li><li><b>Chlamydial infection:<\/b> 1 g ORALLY as a single dose<\/li><li><b>Community acquired pneumonia (Mild to Moderate):<\/b> tablets, 500 mg ORALLY on day 1 followed by 250 mg\/day ORALLY on days 2 to 5<\/li><li><b>Community acquired pneumonia (Mild to Moderate):<\/b> extended-release suspension, a single 2 g ORAL dose<\/li><li><b>Community acquired pneumonia (Mild to Moderate):<\/b> IV, 500 mg IV every day for at least 2 days followed by 500 mg ORALLY every day to complete a 7 to 10 day course of therapy<\/li><li><b>Cystic fibrosis:<\/b> less than 40 kg, 250 mg ORALLY 3 times per week was the dosage used in 2 clinical studies<\/li><li><b>Cystic fibrosis:<\/b> 40 kg or greater, 500 mg ORALLY 3 times per week was the dosage used in 2 clinical studies<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group; Prophylaxis - HIV infection:<\/b> (primary prevention) 1200 mg ORALLY once weekly OR 600 mg ORALLY twice weekly<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group; Prophylaxis - HIV infection:<\/b> (secondary prevention) 500 to 600 mg ORALLY daily in combination with ethambutol 15 mg\/kg ORALLY daily, with or without rifabutin 300 mg ORALLY daily<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group - HIV infection:<\/b> 500 to 600 mg ORALLY daily in combination with ethambutol 15 mg\/kg ORALLY daily, with or without rifabutin 300 mg ORALLY daily<\/li><li><b>Gonorrhea, Urethritis or cervicitis:<\/b> a single 1 g dose ORALLY plus a single dose of either ceftriaxone 250 mg IM or cefixime 400 mg ORALLY; monotherapy with azithromycin 2 g single dose is not recommended due to concerns regarding the development of macrolide resistance<\/li><li><b>Granuloma inguinale:<\/b> 1 g ORALLY once weekly for at least 3 weeks and until all lesions have completely healed<\/li><li><b>HIV infection - Toxoplasma encephalitis:<\/b> (alternative therapy) 900 to 1200 mg ORALLY daily, in combination with pyrimethamine 200 mg ORALLY for 1 dose, then 50 mg (less than 60 kg) or 75 mg (60 kg or greater) ORALLY daily plus leucovorin 10 to 25 mg (can increase to 50 mg) ORALLY daily for at least 6 weeks<\/li><li><b>Infection of skin AND\/OR subcutaneous tissue, Uncomplicated:<\/b> 500 mg ORALLY on day 1 followed by 250 mg\/day ORALLY on days 2 to 5<\/li><li><b>Lyme disease:<\/b> (alternative to first-line therapy) 500 mg ORALLY once daily for 7 to 10 days for early localized or early disseminated Lyme disease associated with erythema migrans or borrelial lymphocytoma<\/li><li><b>Mycobacterium avium complex infection, Lung disease:<\/b> (nodular\/bronchiectatic disease) initial, 500 to 600 mg ORALLY 3 times weekly in combination with ethambutol 25 mg\/kg 3 times weekly and rifampin 600 mg 3 times weekly<\/li><li><b>Mycobacterium avium complex infection, Lung disease:<\/b> (cavitary disease) initial, 250 mg ORALLY daily in combination with ethambutol 15 mg\/kg daily and rifampin 10 mg\/kg daily (MAX 600 mg daily); consider addition of streptomycin OR amikacin<\/li><li><b>Mycobacterium avium complex infection, Lung disease:<\/b> (severe or previously treated disease) initial, 250 to 300 mg ORALLY daily in combination with ethambutol 15 mg\/kg daily and rifabutin 150 to 300 mg daily OR rifampin 10 mg\/kg daily (MAX 600 mg daily); plus streptomycin OR amikacin<\/li><li><b>Nongonococcal cervicitis:<\/b> 1 g ORALLY as a single dose<\/li><li><b>Nongonococcal urethritis:<\/b> 1 g ORALLY as a single dose<\/li><li><b>Pelvic inflammatory disease:<\/b> 500 mg IV every day for 1 or 2 days followed by 250 mg ORALLY every day to complete a 7-day course of therapy<\/li><li><b>Pertussis:<\/b> 500 mg single dose ORALLY on day 1, then 250 mg daily on days 2 through 5 (guideline dosing)<\/li><li><b>Sexually transmitted infectious disease; Prophylaxis - Victim of sexual aggression:<\/b> 1 g ORALLY as a single dose or doxycycline 100 mg ORALLY twice a day for 7 days, plus ceftriaxone 250 mg IM or cefixime 400 mg orally as a single dose plus metronidazole 2 g ORALLY as a single dose<\/li><li><b>Streptococcal pharyngitis, alternative to first-line therapy:<\/b> 12 mg\/kg ORALLY once daily for 5 days; MAX 500 mg\/dose (guideline dosing)<\/li><li><b>Streptococcal pharyngitis, alternative to first-line therapy:<\/b> (tablets and immediate-release suspension) 500 mg single-dose ORALLY on day 1, then 250 mg ORALLY once daily on days 2 through 5 (manufacturer dosing)<\/li><li><b>Streptococcal tonsillitis, alternative to first-line therapy:<\/b> 12 mg\/kg ORALLY once daily for 5 days; MAX 500 mg\/dose (guideline dosing)<\/li><li><b>Streptococcal tonsillitis, alternative to first-line therapy:<\/b> (tablets and immediate-release suspension) 500 mg single-dose ORALLY on day 1, then 250 mg ORALLY once daily on days 2 through 5<\/li><li><b>Traveler's diarrhea:<\/b> 1000 mg ORALLY as a single dose, or 500 mg ORALLY once daily for 3 days<\/li><\/ul>"},{"id":"928480-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Acute otitis media:<\/b> (6 months or older) 30 mg\/kg as single ORAL dose OR 10 mg\/kg ORALLY every day for 3 days OR 10 mg\/kg ORALLY on day 1 followed by 5 mg\/kg ORALLY every day for days 2 to 5 (manufacturer dosing)<\/li><li><b>Babesiosis:<\/b> 10 mg\/kg ORALLY on day 1 (MAX 500 mg\/dose) followed by 5 mg\/kg\/day (MAX 250 mg\/dose) thereafter plus atovaquone 20 mg\/kg ORALLY (MAX 750 mg\/dose) every 12 hours for 7 to 10 days<\/li><li><b>Bacterial conjunctivitis:<\/b> (1 year or older) 1 drop of 1% solution instilled into the affected eye(s) twice daily (8 to 12 hours apart) for 2 days, followed by 1 drop once daily for an additional 5 days<\/li><li><b>Bacterial endocarditis; Prophylaxis:<\/b> (high-risk patients; dental, respiratory, or infected skin\/skin structure or musculoskeletal tissue procedures) 15 mg\/kg ORALLY 30 to 60 minutes prior to procedure<\/li><li><b>Bacterial sinusitis, acute (Mild to Moderate):<\/b> (6 months or older) 10 mg\/kg (MAX 500 mg\/dose) ORALLY once daily for 3 days<\/li><li><b>Bartonellosis - HIV infection:<\/b> (cutaneous bacillary angiomatosis) 5 to 12 mg\/kg (MAX 600 mg\/day) ORALLY once daily for 3 months<\/li><li><b>Chlamydial infection:<\/b> (at least 45 kg or at least 8 years of age) 1 g ORALLY as a single dose<\/li><li><b>Community acquired pneumonia (Mild to Moderate):<\/b> (6 months or older) tablets and immediate-release suspension, 10 mg\/kg (MAX 500 mg\/dose) ORALLY on day 1 followed by 5 mg\/kg (MAX 250 mg\/dose) ORALLY on days 2 to 5 (manufacturer dosing); this dosage is also recommended for outpatient treatment in children older than 3 months (guideline dosing)<\/li><li><b>Community acquired pneumonia (Mild to Moderate):<\/b> (6 months or older) extended-release suspension, less than 34 kg, a single 60-mg\/kg ORAL dose; 34 kg and greater, a single 2-g ORAL dose (manufacturer dosing)<\/li><li><b>Community acquired pneumonia (Mild to Moderate):<\/b> (inpatient treatment; older than 3 months) 10 mg\/kg IV daily for at least 2 days, then 5 mg\/kg ORALLY once daily to complete treatment course<\/li><li><b>Cystic fibrosis:<\/b> 6 years or older (less than 40 kg), 250 mg ORALLY 3 times per week was the dosage used in 2 clinical studies<\/li><li><b>Cystic fibrosis:<\/b> 6 years or older (40 kg or greater), 500 mg ORALLY 3 times per week was the dosage used in 2 clinical studies<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group; Prophylaxis - HIV infection:<\/b> (primary prevention) preferred regimen, 20 mg\/kg ORALLY once weekly (MAX 1200 mg\/week); alternative regimen, 5 mg\/kg ORALLY once daily (MAX 250 mg\/day)<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group; Prophylaxis - HIV infection:<\/b> (secondary prevention) 5 mg\/kg ORALLY daily (MAX 250 mg\/day) in combination with ethambutol 15 to 25 mg\/kg ORALLY daily (MAX 2.5 g\/day), with or without rifabutin 5 mg\/kg ORALLY daily (MAX 300 mg\/day)<\/li><li><b>Disseminated infection due to Mycobacterium avium-intracellulare group - HIV infection:<\/b> 10 to 12 mg\/kg ORALLY once daily (MAX 500 mg\/day) in combination with ethambutol 15 to 25 mg\/kg ORALLY once daily (MAX 2.5 g\/day); for severe disease, add rifabutin 10 to 20 mg\/kg ORALLY once daily (MAX 300 mg\/day)<\/li><li><b>Gonococcal conjunctivitis neonatorum; Prophylaxis:<\/b> (during erythromycin ophthalmic ointment shortage) 1 to 2 drops placed in the conjunctival sac of each EYE; closely monitor for prophylaxis failure 48 to 72 hours postdischarge<\/li><li><b>Lyme disease:<\/b> (alternative to first-line therapy) 10 mg\/kg\/day ORALLY for 7 to 10 days for early localized or early disseminated Lyme disease associated with erythema migrans or borrelial lymphocytoma; MAX 500 mg\/day<\/li><li><b>Pertussis:<\/b> (younger than 6 months) 10 mg\/kg\/day single dose ORALLY for 5 days; (6 months or older) 10 mg\/kg single dose ORALLY on day 1 (MAX 500 mg), then 5 mg\/kg\/day on days 2 through 5 (MAX 250 mg) (guideline dosing)<\/li><li><b>Streptococcal pharyngitis, alternative to first-line therapy:<\/b> 12 mg\/kg ORALLY once daily for 5 days; MAX 500 mg\/dose (guideline dosing)<\/li><li><b>Streptococcal pharyngitis, alternative to first-line therapy:<\/b> (tablets and immediate-release suspension; 2 years or older) 12 mg\/kg ORALLY daily for 5 days<\/li><li><b>Streptococcal tonsillitis, alternative to first-line therapy:<\/b> 12 mg\/kg ORALLY once daily for 5 days; MAX 500 mg\/dose (guideline dosing)<\/li><li><b>Streptococcal tonsillitis, alternative to first-line therapy:<\/b> (tablets and immediate-release suspension; 2 years or older) 12 mg\/kg ORALLY daily for 5 days<\/li><li><b>Traveler's diarrhea:<\/b> 10 mg\/kg ORALLY once daily for 3 days<\/li><\/ul>"},{"id":"928480-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment, GFR 80 mL\/min or less:<\/b> no dose adjustment necessary<\/li><li><b>renal impairment, GFR less than 10 mL\/min:<\/b> use with caution<\/li><li><b>hepatic impairment, cirrhosis:<\/b> no dose adjustment necessary<\/li><li><b>geriatric:<\/b> no dose adjustment necessary<\/li><\/ul>"},{"id":"928480-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acute infective exacerbation of chronic obstructive pulmonary disease (Mild to Moderate)<\/li><li>Acute otitis media<\/li><li>Bacterial conjunctivitis<\/li><li>Bacterial sinusitis, acute (Mild to Moderate)<\/li><li>Chancroid<\/li><li>Community acquired pneumonia (Mild to Moderate)<\/li><li>Gonorrhea, Urethritis or cervicitis<\/li><li>Infection of skin AND\/OR subcutaneous tissue, Uncomplicated<\/li><li>Nongonococcal cervicitis<\/li><li>Nongonococcal urethritis<\/li><li>Pelvic inflammatory disease<\/li><li>Streptococcal pharyngitis, alternative to first-line therapy<\/li><li>Streptococcal tonsillitis, alternative to first-line therapy<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Babesiosis<\/li><li>Bacterial endocarditis; Prophylaxis<\/li><li>Bartonellosis - HIV infection<\/li><li>Chlamydial infection<\/li><li>Cholera<\/li><li>Cystic fibrosis<\/li><li>Disseminated infection due to Mycobacterium avium-intracellulare group; Prophylaxis - HIV infection<\/li><li>Disseminated infection due to Mycobacterium avium-intracellulare group - HIV infection<\/li><li>Drug-induced gingival hyperplasia<\/li><li>Gonococcal conjunctivitis neonatorum; Prophylaxis<\/li><li>Granuloma inguinale<\/li><li>Helicobacter pylori gastrointestinal tract infection<\/li><li>HIV infection - Toxoplasma encephalitis<\/li><li>Legionella infection<\/li><li>Lyme disease<\/li><li>Mycobacterium avium complex infection, Lung disease<\/li><li>Pertussis<\/li><li>Sexually transmitted infectious disease; Prophylaxis - Victim of sexual aggression<\/li><li>Shigellosis<\/li><li>Trachoma<\/li><li>Traveler's diarrhea<\/li><li>Typhoid fever<\/li><\/ul>"}]},"3":{"id":"928480-s-3","title":"Contraindications\/Warnings","sub":[{"id":"928480-s-3-9","title":"Contraindications","mono":"<ul><li>hepatic dysfunction with prior azithromycin therapy<\/li><li>hypersensitivity to azithromycin or to any product component, erythromycin, or any macrolide or ketolide antibiotic<\/li><li>jaundice, cholestatic, with prior azithromycin therapy<\/li><\/ul>"},{"id":"928480-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- QT interval prolongation has been reported, including cases of torsade de pointes especially in patients with known or congenital QT prolongation, history of torsade de pointes, bradyarrhythmias, uncompensated heart failure, proarrhythmic conditions, or patients on concomitant drugs known to prolong the QT interval<\/li><li>Dermatologic:<\/li><li>-- localized IV site reactions have been reported; avoid higher concentrations, especially above 2 mg\/mL<\/li><li>Hepatic:<\/li><li>-- hepatotoxicity, including abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure, with some fatalities, has been reported; discontinue immediately if signs and symptoms of hepatitis occur<\/li><li>-- use caution in patients with hepatic impairment since azithromycin mainly eliminated via liver<\/li><li>Immunologic:<\/li><li>-- serious and sometimes fatal allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported; immediate discontinuation recommended; however, recurrence of allergic symptoms without further azithromycin exposure may occur<\/li><li>Musculoskeletal:<\/li><li>-- new onset or exacerbation of myasthenia gravis has been reported<\/li><li>Ophthalmic:<\/li><li>-- avoid contact lenses if signs\/symptoms of bacterial conjunctivitis present<\/li><li>Renal:<\/li><li>-- use caution in patients with severe renal function impairment (GFR less than 10 mL\/min); higher incidence of gastrointestinal adverse events reported (Zmax(R))<\/li><li>Other:<\/li><li>-- elderly patients are at possible increased risk of QT-interval prolongation and torsade de pointes<\/li><li>-- prolonged use of ophthalmic solution may result in overgrowth of nonsusceptible microorganisms, including fungi; discontinue if superinfection develops<\/li><li>Concomitant use:<\/li><li>-- avoid class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmics due to increased risk of QT prolongation and torsade de pointes<\/li><\/ul>"},{"id":"928480-s-3-11","title":"Pregnancy Category","mono":"<ul><li>B (FDA)<\/li><li>B1 (AUS)<\/li><\/ul>"},{"id":"928480-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk is minimal.<br\/>"}]},"4":{"id":"928480-s-4","title":"Drug Interactions","sub":[{"id":"928480-s-4-13","title":"Contraindicated","mono":"<ul><li>Amifampridine (theoretical)<\/li><li>Bepridil (theoretical)<\/li><li>Cisapride (theoretical)<\/li><li>Colchicine (theoretical)<\/li><li>Dihydroergotamine (probable)<\/li><li>Dronedarone (theoretical)<\/li><li>Ergoloid Mesylates (probable)<\/li><li>Ergonovine (probable)<\/li><li>Ergotamine (probable)<\/li><li>Methylergonovine (probable)<\/li><li>Methysergide (probable)<\/li><li>Pimozide (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sparfloxacin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Thioridazine (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><\/ul>"},{"id":"928480-s-4-14","title":"Major","mono":"<ul><li>Acecainide (theoretical)<\/li><li>Afatinib (theoretical)<\/li><li>Alfuzosin (theoretical)<\/li><li>Amiodarone (theoretical)<\/li><li>Amitriptyline (theoretical)<\/li><li>Amoxapine (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Apomorphine (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Arsenic Trioxide (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Astemizole (theoretical)<\/li><li>Azimilide (theoretical)<\/li><li>Bosutinib (theoretical)<\/li><li>Bretylium (theoretical)<\/li><li>Buserelin (theoretical)<\/li><li>Chloroquine (theoretical)<\/li><li>Chlorpromazine (theoretical)<\/li><li>Ciprofloxacin (theoretical)<\/li><li>Citalopram (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Clomipramine (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Crizotinib (theoretical)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Dasatinib (theoretical)<\/li><li>Degarelix (theoretical)<\/li><li>Delamanid (theoretical)<\/li><li>Desipramine (theoretical)<\/li><li>Deslorelin (theoretical)<\/li><li>Disopyramide (probable)<\/li><li>Dofetilide (theoretical)<\/li><li>Dolasetron (theoretical)<\/li><li>Domperidone (theoretical)<\/li><li>Donepezil (probable)<\/li><li>Doxorubicin (theoretical)<\/li><li>Doxorubicin Hydrochloride Liposome (theoretical)<\/li><li>Droperidol (theoretical)<\/li><li>Erythromycin (theoretical)<\/li><li>Escitalopram (theoretical)<\/li><li>Everolimus (theoretical)<\/li><li>Fingolimod (theoretical)<\/li><li>Flecainide (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fluoxetine (theoretical)<\/li><li>Gatifloxacin (theoretical)<\/li><li>Gemifloxacin (theoretical)<\/li><li>Gonadorelin (theoretical)<\/li><li>Goserelin (theoretical)<\/li><li>Granisetron (theoretical)<\/li><li>Halofantrine (theoretical)<\/li><li>Haloperidol (theoretical)<\/li><li>Histrelin (theoretical)<\/li><li>Hydroxychloroquine (probable)<\/li><li>Ibutilide (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Imipramine (theoretical)<\/li><li>Ivabradine (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lapatinib (theoretical)<\/li><li>Leuprolide (theoretical)<\/li><li>Levofloxacin (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lumefantrine (theoretical)<\/li><li>Mefloquine (theoretical)<\/li><li>Methadone (theoretical)<\/li><li>Metronidazole (theoretical)<\/li><li>Mifepristone (theoretical)<\/li><li>Morphine (theoretical)<\/li><li>Morphine Sulfate Liposome (theoretical)<\/li><li>Moxifloxacin (theoretical)<\/li><li>Nafarelin (theoretical)<\/li><li>Nilotinib (theoretical)<\/li><li>Norfloxacin (theoretical)<\/li><li>Nortriptyline (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Ofloxacin (theoretical)<\/li><li>Ombitasvir (theoretical)<\/li><li>Ondansetron (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Panobinostat (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Pazopanib (theoretical)<\/li><li>Perflutren Lipid Microsphere (theoretical)<\/li><li>Pixantrone (theoretical)<\/li><li>Pomalidomide (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Procainamide (theoretical)<\/li><li>Prochlorperazine (theoretical)<\/li><li>Promethazine (theoretical)<\/li><li>Propafenone (theoretical)<\/li><li>Protriptyline (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Quinine (theoretical)<\/li><li>Ranolazine (theoretical)<\/li><li>Romidepsin (theoretical)<\/li><li>Salmeterol (theoretical)<\/li><li>Sematilide (theoretical)<\/li><li>Sevoflurane (theoretical)<\/li><li>Simvastatin (probable)<\/li><li>Sodium Phosphate (theoretical)<\/li><li>Sodium Phosphate, Dibasic (theoretical)<\/li><li>Sodium Phosphate, Monobasic (theoretical)<\/li><li>Solifenacin (theoretical)<\/li><li>Sorafenib (theoretical)<\/li><li>Sotalol (theoretical)<\/li><li>Sunitinib (theoretical)<\/li><li>Tedisamil (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tetrabenazine (theoretical)<\/li><li>Topotecan (theoretical)<\/li><li>Toremifene (theoretical)<\/li><li>Trabectedin (theoretical)<\/li><li>Trazodone (theoretical)<\/li><li>Trifluoperazine (theoretical)<\/li><li>Trimipramine (theoretical)<\/li><li>Triptorelin (theoretical)<\/li><li>Vandetanib (theoretical)<\/li><li>Vardenafil (theoretical)<\/li><li>Vemurafenib (theoretical)<\/li><li>Vincristine (theoretical)<\/li><li>Vincristine Sulfate Liposome (theoretical)<\/li><li>Vinflunine (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><li>Warfarin (probable)<\/li><\/ul>"},{"id":"928480-s-4-15","title":"Moderate","mono":"<ul><li>Atorvastatin (probable)<\/li><li>Digoxin (probable)<\/li><li>Fentanyl (probable)<\/li><li>Lovastatin (probable)<\/li><li>Nelfinavir (probable)<\/li><li>Rifabutin (probable)<\/li><li>Theophylline (probable)<\/li><\/ul>"}]},"5":{"id":"928480-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction (3.1% to 6.5%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (adult, 1.9% to 14%; pediatric, 2% to 4%), Diarrhea (adult, 4.3% to 12%; pediatric, 7% to 10%), Flatulence (5%), Nausea (adult, 3% to 14%; pediatric, 4%), Vomiting (adult, up to 13%; pediatric, 11% to 14%)<\/li><li><b>Hepatic:<\/b>Increased liver enzymes (less than 1% to 6%)<\/li><li><b>Neurologic:<\/b>Headache (up to 5%)<\/li><li><b>Ophthalmic:<\/b>Abnormal vision (5%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Prolonged QT interval, Torsades de pointes<\/li><li><b>Hepatic:<\/b>Hepatic necrosis, Hepatitis (less than 1%), Liver failure<\/li><li><b>Immunologic:<\/b>Drug hypersensitivity syndrome, Hypersensitivity reaction<\/li><li><b>Musculoskeletal:<\/b>Eaton-Lambert syndrome, Myasthenia gravis, Exacerbation of, Myasthenic crisis<\/li><li><b>Ophthalmic:<\/b>Corneal erosion (less than 1%)<\/li><\/ul>"},"6":{"id":"928480-s-6","title":"Drug Name Info","sub":{"0":{"id":"928480-s-6-17","title":"US Trade Names","mono":"<ul><li>Zithromax<\/li><li>Zithromax Tri-Pak<\/li><li>Zithromax Z-Pak<\/li><li>Zmax<\/li><li>AzaSite<\/li><\/ul>"},"2":{"id":"928480-s-6-19","title":"Class","mono":"<ul><li>Antibiotic<\/li><li>Macrolide<\/li><\/ul>"},"3":{"id":"928480-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"928480-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"928480-s-7","title":"Mechanism Of Action","mono":"Azithromycin binds to the 50S ribosomal subunit of susceptible microorganisms, thus, interfering with microbial protein synthesis.<br\/>"},"8":{"id":"928480-s-8","title":"Pharmacokinetics","sub":[{"id":"928480-s-8-23","title":"Absorption","mono":"<ul><li>Tablets: time to peak concentration, 2.2 to 3.2 h<\/li><li>Bioavailability: 38%<\/li><li>Effects of food: minimal, no effect on AUC<\/li><\/ul>"},{"id":"928480-s-8-24","title":"Distribution","mono":"<ul><li>Vd: (Intravenous) 33.3 L\/kg<\/li><li>Vd: (Oral) 31.1 L\/kg<\/li><li>Protein binding: 7% to 51% (concentration dependent)<\/li><\/ul>"},{"id":"928480-s-8-25","title":"Metabolism","mono":"Hepatic; 35%.<br\/>"},{"id":"928480-s-8-26","title":"Excretion","mono":"<ul><li>Biliary: major route for unchanged drug<\/li><li>Renal: (Oral) 6% unchanged<\/li><li>Renal: (Intravenous) 11% to 14% unchanged<\/li><\/ul>"},{"id":"928480-s-8-27","title":"Elimination Half Life","mono":"Adults: 68 h <br\/>"}]},"9":{"id":"928480-s-9","title":"Administration","mono":"<ul><li><b>Intravenous<\/b><br\/><ul><li>infusion only; do not give IV bolus or IM<\/li><li>reconstitute with sterile water for injection; dilute in NS, D5W, or LR to final concentration of 1 to 2 mg\/mL<\/li><li>infuse at 1 mg\/mL over 3 hours or 2 mg\/mL over 1 hour; do not infuse over less than 60 minutes (500-mg dose)<\/li><\/ul><\/li><li><b>Ophthalmic<\/b><br\/><ul><li>for topical ophthalmic use only; do not administer systemically or directly into the anterior chamber of the eye; do not inject subconjunctivally<\/li><li>avoid touching the tip of applicator to eye or fingers<\/li><li>shake once prior to each use while bottle is inverted; remove cap while bottle is still inverted<\/li><\/ul><\/li><li><b>Oral<\/b><br\/><ul><li>(extended-release suspension) take on an empty stomach (at least 1 hour before or 2 hours following a meal)<\/li><li>(tablets and immediate-release suspension) take with or without food<\/li><li>do not give simultaneously with aluminum- or magnesium-containing antacids<\/li><li>(suspension) shake well before measuring dose<\/li><li>(extended-release suspension) if vomiting occurs within 60 minutes of ingestion, additional antibiotic therapy may be considered, as there would be minimal azithromycin absorption within this time period<\/li><li>(extended-release suspension) if vomiting occurs 60 minutes or greater following a dose, a second dose or alternative therapy is not required in patients with normal gastric emptying<\/li><\/ul><\/li><\/ul>"},"10":{"id":"928480-s-10","title":"Monitoring","mono":"<ul><li>symptomatic improvement<\/li><li>fever<\/li><li>CBC<\/li><li>hepatic function (history of hepatic impairment)<\/li><\/ul>"},"11":{"id":"928480-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Intravenous Powder for Solution: 500 MG<\/li><li>Oral Powder for Suspension: 1 GM\/Packet, 100 MG\/5 ML, 200 MG\/5 ML<\/li><li>Oral Tablet: 250 MG, 500 MG, 600 MG<\/li><\/ul><\/li><li><b>Amerinet Choice Zithromax<\/b><br\/>Intravenous Powder for Solution: 500 MG<br\/><\/li><li><b>AzaSite<\/b><br\/>Ophthalmic Solution: 1 %<br\/><\/li><li><b>PremierPro Rx Azithromycin<\/b><br\/>Intravenous Powder for Solution: 500 MG<br\/><\/li><li><b>Zithromax<\/b><br\/><ul><li>Intravenous Powder for Solution: 500 MG<\/li><li>Oral Powder for Suspension: 1 GM\/Packet, 100 MG\/5 ML, 200 MG\/5 ML<\/li><li>Oral Tablet: 250 MG, 500 MG, 600 MG<\/li><\/ul><\/li><li><b>Zithromax Tri-Pak<\/b><br\/>Oral Tablet: 500 MG<br\/><\/li><li><b>Zithromax Z-Pak<\/b><br\/>Oral Tablet: 250 MG<br\/><\/li><li><b>Zmax<\/b><br\/>Oral Powder for Suspension, Extended Release: 2 GM\/60 ML<br\/><\/li><\/ul>"},"12":{"id":"928480-s-12","title":"Toxicology","sub":[{"id":"928480-s-12-31","title":"Clinical Effects","mono":"<b>MACROLIDE ANTIBIOTICS <\/b><br\/>OVERDOSE: Significant toxicity following acute overdose is uncommon.  N\/V, abdominal pain may occur.  ADVERSE EFFECTS: N\/V, abdominal pain, diarrhea most common.  Cholestasis, sensorineural hearing loss, thrombophlebitis (IV administration), ventricular dysrhythmias\/QT prolongation (IV administration) are less common. <br\/>"},{"id":"928480-s-12-32","title":"Treatment","mono":"<b>MACROLIDE ANTIBIOTICS <\/b><br\/><ul><li>Decontamination: Activated charcoal, gastric lavage.<\/li><li>Support: Therapy as indicated.<\/li><li>Abdominal discomfort: Food, milk or an antacid  may be given; most effects reverse with drug cessation<\/li><li>Monitoring of patient: Baseline ECG, cardiac monitoring as indicated. Renal and hepatic function as indicated.<\/li><\/ul>"},{"id":"928480-s-12-33","title":"Range of Toxicity","mono":"<b>MACROLIDE ANTIBIOTICS<\/b><br\/>In general, the macrolide antibiotics are of a low order toxicity. <br\/>"}]},"13":{"id":"928480-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to immediately report signs\/symptoms of hepatotoxicity or Clostridium difficile-associated diarrhea (severe, watery, or bloody diarrhea).<\/li><li>Counsel patient using ophthalmic solution to avoid using contact lenses with signs\/symptoms of bacterial conjunctivitis and to prevent contamination of solution.<\/li><li>Ophthalmic solution may cause blurred vision, eye pain, eye irritation, eye pruritus, and facial swelling..<\/li><li>Drug may cause headache, dizziness, rash, abdominal pain, dyspepsia, flatulence, nausea, vomiting, or injection site pain (IV).<\/li><li>Instruct patient taking extended-release suspension (Zmax(R)) to take solution within 12 hours of reconstitution and immediately discard any unused portion.<\/li><li>Tell patient taking extended-release suspension (Zmax(R)) to take dose on an empty stomach and call physician if patient vomits within 1 hour after administration.<\/li><li>Advise patient on proper instillation technique for ophthalmic preparation..<\/li><li>Instruct patient using oral tablets and regular suspension to avoid concomitant use of aluminum or magnesium-containing antacids. The extended-release suspension (Zmax(R)) may be taken with antacids.<\/li><\/ul>"}}}